Lombard Medical (NASDAQ: EVAR) and Antares Pharma (NASDAQ:ATRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitabiliy, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Lombard Medical and Antares Pharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lombard Medical 0 2 0 0 2.00
Antares Pharma 0 0 3 1 3.25

Lombard Medical currently has a consensus price target of $1.00, indicating a potential upside of 108.33%. Antares Pharma has a consensus price target of $4.58, indicating a potential upside of 46.63%. Given Lombard Medical’s higher possible upside, analysts plainly believe Lombard Medical is more favorable than Antares Pharma.

Insider and Institutional Ownership

62.2% of Lombard Medical shares are held by institutional investors. Comparatively, 31.7% of Antares Pharma shares are held by institutional investors. 11.6% of Antares Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Lombard Medical has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.

Valuation and Earnings

This table compares Lombard Medical and Antares Pharma’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Lombard Medical $12.17 million 1.10 -$24.22 million ($1.54) -0.31
Antares Pharma $51.91 million 9.37 -$19.23 million ($0.14) -22.29

Antares Pharma has higher revenue and earnings than Lombard Medical. Antares Pharma is trading at a lower price-to-earnings ratio than Lombard Medical, indicating that it is currently the more affordable of the two stocks.


This table compares Lombard Medical and Antares Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lombard Medical -255.03% -124.24% -41.26%
Antares Pharma -39.44% -43.86% -29.53%


Antares Pharma beats Lombard Medical on 11 of the 14 factors compared between the two stocks.

Lombard Medical Company Profile

Lombard Medical, Inc. is a medical technology company. The Company specializes in developing, manufacturing, and marketing endovascular stent-grafts that address medical needs in the repair of aortic aneurysms. The Company’s Aorfix is an abdominal aortic aneurysm (AAA) stent-graft for the treatment of AAAs with angulation at the neck of the aneurysm of over 90 degrees. The Company supplies Aorfix pre-loaded into a delivery system, Aorflex, which is designed for accurate placement of Aorfix in the abdominal aorta. Once Aorfix is properly placed within the abdominal aorta, it provides a conduit for blood flow, thereby relieving pressure within the weakened or aneurysmal section of the vessel wall, which reduces the potential for the AAA to rupture. It also offers IntelliFlex, which is a delivery system technology created for Aorfix AAA stent graft, and Altura Endovascular Stent Graft System that offers a simple and predictable solution to the treatment of standard AAA anatomies.

Antares Pharma Company Profile

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies.

Receive News & Ratings for Lombard Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lombard Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.